Gastroesophageal reflux disease: how to optimize patient management?
DOI: 10.32364/2587-6821-2024-8-5-5
M.A. Livzan1, O.V. Gaus1, S.I. Mozgovoy1, D.S. Bordin2–4, D.A. Gavrilenko1
1Omsk State Medical University, Omsk, Russian Federation
2A.S. Loginov Moscow Clinical Scientific Center, Moscow, Russian Federation
3Russian University of Medicine, Moscow, Russian Federation
4Tver State Medical University, Tver, Russian Federation
Gastroesophageal reflux disease (GERD) is widespread in the population due to the high incidence of its risk factors. Among these factors, epigenetic factors (excess body weight, obesity, smoking, the use of drugs that promote relaxation of the lower esophageal sphincter, hiatal hernia, etc.) play a significant role. The impact of these factors is primarily manifested through the development of persistent motor disorders at the esophagogastric junction. Furthermore, it is essential to consider the aggressive and protective factors of the esophageal mucosa when evaluating the risk of disease progression and categorizing patients at high risk for erosive reflux esophagitis and Barrett's esophagus in the general cohort of patients with GERD. A treatment approach based on risk factor modification and the use of combination therapy with a proton pump inhibitor and an esophageal protector has been demonstrated to enhance the efficacy of GERD treatment in a number of ways. Firstly, it has been shown to facilitate the achievement of clinical, endoscopic and histological remission. Secondly, it has been shown to prevent disease progression, particularly in patients at high risk for erosive reflux disease and Barrett's esophagus.
KEYWORDS: gastroesophageal reflux disease, reflux esophagitis, erosive gastroesophageal reflux disease, Barrett's esophagus, epithelium-protective therapy, esophagoprotector.
For citation: Livzan M.A., Gaus O.V., Mozgovoy S.I., Bordin D.S., Gavrilenko D.A. Gastroesophageal reflux disease: how to optimize patient management? Russian Medical Inquiry. 2024;8(5):274–280 (in Russ.). DOI: 10.32364/2587-6821-2024-8-5-.
ABOUT THE AUTHORS:
Maria A. Livzan — Dr. Sc. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Faculty Therapy and Gastroenterology, rector, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6581-7017.
Olga V. Gaus — C. Sc. (Med.), Assistant Professor of the Department of Faculty Therapy and Gastroenterology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0001-9370-4768.
Sergei I. Mozgovoy — Dr. Sc. (Med.), Associate Professor, Professor of the Department of Pathological Anatomy, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6733-5572.
Dmitriy S. Bordin — Dr. Sc. (Med.), Head of the Department of Pancreatic, Biliary, and Upper Gastrointestinal Disorders, A.S. Loginov Moscow Clinical Scientific Center; 1, build., 1, Novogireevskaya str., Moscow, 111123, Russian Federation; professor of the Department of Propaedeutics of Internal Diseases and Gastroenterology, Russian University of Medicine; 4, Dolgorukovskaya str., Moscow, 127006, Russian Federation; professor of the Department of General Medical Practice and Family Medicine, Tver State Medical University; 4, Sovetskaya str., Tver, 170100, Russian Federation; ORCID iD 0000-0003-2815-3992.
Darya A. Gavrilenko — 1st year resident of the Department of Faculty Therapy and Gastroenterology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0001-5245-719.
Contact information: Olga V. Gaus, e-mail: gaus_olga@bk.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 20.02.2024.
Revised 19.03.2024.
Accepted 11.04.2024.
2. Argyrou A., Legaki E., Koutserimpas C. et al. Risk factors for gastroesophageal reflux disease and analysis of genetic contributors. World J Clin Cases. 2018;6(8):176–182. DOI: 10.12998/wjcc.v6.i8.176.
3. Eusebi L.H., Ratnakumaran R., Yuan Y. et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440. DOI: 10.1136/gutjnl-2016-313589.
4. Zheng Z., Nordenstedt H., Pedersen N.L. et al. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. Gastroenterology. 2007;132(1):87–95. DOI: 10.1053/j.gastro.2006.11.019.
5. Zhang M., Hou Z.K., Huang Z.B. et al. Dietary and Lifestyle Factors Related to Gastroesophageal Reflux Disease: A Systematic Review. Ther Clin Risk Manag. 2021;17:305–323. DOI: 10.2147/TCRM.S296680.
6. Znamirowski P., Kołomańska M., Mazurkiewicz R. et al. GERD as a complication of laparoscopic sleeve gastrectomy for the treatment of obesity: a systematic review and meta-analysis. J Pers Med. 2023;13(8):1243. DOI: 10.3390/jpm13081243.
7. Maev I.V., Livzan M.A., Mozgovoi S.I. et al. Esophageal Mucosal Resistance in Reflux Esophagitis: What We Have Learned So Far and What Remains to Be Learned. Diagnostics. 2023;13(16):2664. DOI: 10.3390/diagnostics13162664.
8. Rieder F., Biancani P., Harnett K. et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G571–G581. DOI: 10.1152/ajpgi.00454.2009.
9. Franklin J., Jankowski J. Recent advances in understanding and preventing oesophageal cancer. F1000Res. 2020;9:F1000 Faculty Rev-276. DOI: 10.12688/f1000research.21971.1.
10. Vakil N., van Zanten S.V., Kahrilas P. et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1943. DOI: 10.1111/j.1572-0241.2006.00630.x.
11. Katz P.O., Dunbar K.B., Schnoll-Sussman F.H. et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27–56. DOI: 10.14309/ajg.0000000000001538.
12. Zagari R.M., Fuccio L., Wallander M.A. et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354–1359. DOI: 10.1136/gut.2007.145177.
13. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70–97. DOI: 10.22416/1382-4376-2020-30-4-70-97.Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97 (in Russ.). DOI: 10.22416/1382-4376-2020-30-4-70-97.
14. Бакулин И.Г., Бордин Д.С., Драпкина О.М. и др. Фенотипы гастроэзофагеальной рефлюксной болезни в реальной клинической практике. Consilium Medicum. 2019;2(8):15–22. DOI: 10.26442/20751753.2019.8.190581.Bakulin I.G., Bordin D.S., Drapkina O.M. et al. Phenotypes of Gastroesophageal Reflux Disease in real clinical practice. Consilium Medicum. 2019;21(8):15–22 (in Russ.). DOI: 10.26442/20751753.2019.8.190581.
15. Savarino E., Zentilin P., Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol. 2013;10(6):371–380. DOI: 10.1038/nrgastro.2013.50.
16. Gaddam S., Wani S., Ahmed H. et al. The impact of pre-endoscopy proton pump inhibitor use on the classification of non-erosive reflux disease and erosive oesophagitis. Aliment Pharmacol Ther. 2010;32(10):1266–1274. DOI: 10.1111/j.1365-2036.2010.04468.x.
17. Матошина И.В., Ливзан М.А., Федорин М.М., Лаптева И.В. Клинически значимые стигмы выраженности ГЭРБ и диссоциация со степенью повреждения слизистой пищевода — обязательность эзофагопротекции? Экспериментальная и клиническая гастроэнтерология. 2021;190(6):5–11. DOI: 10.31146/1682-8658-ecg-190-6-5-11.Matoshina I.V., Livzan M.A., Fedorin M.M., Lapteva I.V. Clinically significant stigmas of the severity of GERD and dissociation with the degree of damage to the esophageal mucosa — the obligatory esophagoprotection? Experimental and Clinical Gastroenterology. 2021;1(6):5–11 (in Russ.). DOI: 10.31146/1682-8658-ecg-190-6-5-11.
18. Witarto A.P., Witarto B.S., Pramudito S.L. et al. Risk factors and 26-years worldwide prevalence of endoscopic erosive esophagitis from 1997 to 2022: a meta-analysis. Sci Rep. 2023;13(1):15249. DOI: 10.1038/s41598-023-42636-7.
19. Mocanu M.A., Diculescu M., Dumitrescu M. Gastroesophageal reflux and metabolic syndrome. Rev Med Chir Soc Med Nat Iasi. 2013;117(3):605–609. PMID: 24502023.
20. Fennerty M.B. The continuum of GERD complications. Cleve Clin J Med. 2003;70 Suppl 5:S33–S50. DOI: 10.3949/ccjm.70.suppl_5.s33.
21. Kim Y.S., Kim N., Kim G.H. Sex and Gender Differences in Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2016;22(4):575–588. DOI: 10.5056/jnm16138.
22. Honda J., Iijima K., Asanuma K. et al. Estrogen Enhances Esophageal Barrier Function by Potentiating Occludin Expression. Dig Dis Sci. 2016;61(4):1028–1038. DOI: 10.1007/s10620-015-3980-6.
23. Shaheen N.J., Falk G.W., Iyer P.G. et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am J Gastroenterol. 2022;117(4):559–587. DOI: 10.14309/ajg.0000000000001680.
24. Mejza M., Małecka-Wojciesko E. Diagnosis and Management of Barrett's Esophagus. J Clin Med. 2023;12(6):2141. DOI: 10.3390/jcm12062141.
25. Ness-Jensen E., Hveem K., El-Serag H., Lagergren J. Lifestyle Intervention in Gastroesophageal Reflux Disease. Clin Gastroenterol Hepatol. 2016;14(2):175–182.e1–3. DOI: 10.1016/j.cgh.2015.04.176.
26. Chen J.W., Vela M.F., Peterson K.A., Carlson D.A. AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review. Clin Gastroenterol Hepatol. 2023;21(6):1414–1421.e3. DOI: 10.1016/j.cgh.2023.01.040.
27. Sethi S., Richter J.E. Diet and gastroesophageal reflux disease: role in pathogenesis and management. Curr Opin Gastroenterol. 2017;33(2):107–111. DOI: 10.1097/MOG.0000000000000337.
28. Shin J.M., Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528–534. DOI: 10.1007/s11894-008-0098-4.
29. Weijenborg P.W., Cremonini F., Smout A.J., Bredenoord A.J. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24(8):747–757, e350. DOI: 10.1111/j.1365-2982.2012.01888.x.
30. Кайбышева В.О., Сторонова О.А., Трухманов А.С., Ивашкин В.Т. Возможности внутрипищеводной рН-импедансометрии в диагностике ГЭРБ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013;(2):4–12.Kaybysheva V.O., Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Potentials of intraesophageal pH-impedance measurement in GERD diagnostics. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;(2):4–12 (in Russ.).
31. Ливзан М.А., Бордин Д.С., Гаус О.В., Лисовский М.А. Прокинетики: роль в терапии больного ГЭРБ. РМЖ. Медицинское обозрение. 2023;7(5):283–291. DOI: 10.32364/2587-6821-2023-7-5-6.Livzan M.A., Bordin D.S., Gaus O.V., Lisovsky M.A. Prokinetics: the role in the therapy of a patient with GERD. Russian Medical Inquiry. 2023;7(5):283–291 (in Russ.). DOI: 10.32364/2587-6821-2023-7-5-6.
32. Матошина И.В., Мозговой С.И., Ливзан М.А., Федорин М.М. Новые возможности терапии эрозивной формы гастроэзофагеальной рефлюксной болезни: собственные данные. Современные проблемы науки и образования. 2021;5:86. DOI: 10.17513/spno.31128.Matoshina I.V., Mozgovoy S.I., Livzan M.A., Fedorin M.M. New therapy options for erosive gastroesophageal reflux disease: own data. Sovremennyye problemy nauki i obrazovaniya. 2021;(5):86 (in Russ.)]. DOI: 10.17513/spno.31128.
33. Бордин Д.С., Андреев Д.Н., Маев И.В. Эффективность эзофагопротекции в комплексном лечении эрозивной формы гастро-эзофагеальной рефлюксной болезни: систематический обзор и метаанализ контролируемых исследований. Терапевтический архив. 2022;94(12):1407–1412. DOI: 10.26442/00403660.2022.12.202011.Bordin D.S., Andreev D.N., Maev I.V. Efficacy of esophagus protection in complex treatment of erosive gastroesophageal reflux disease: a systematic review and meta-analysis of controlled trials. Terapevticheskii Arkhiv. 2022;94(12):1407–1412 (in Russ.). DOI: 10.26442/00403660.2022.12.202011.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать